The first immune checkpoint molecule targeted in the clinic, CTLA-4, was analyzed in BC with the presence of CTLA-4+, PD-1+, Helios+, FOXP3+, GITR+, and/or CD103+ Tregs suggestive of an immunosuppressive microenvironment (28, 29). This evidence concerns the gene FOXP3 and breast cancer.